Emotional Stress, Trauma and Cancer

Table of Contents

1. What the Presentation Said
2. Does Stress Raise the Risk of Getting Cancer?
3. Adverse Childhood Experiences and Cancer
4. Stress Hormones and Tumor Growth
5. Depression, Anxiety and Survival
6. Can Psychological Support Extend Survival?
7. Why Two Similar Patients Can Fare Differently
8. What the Research Does Not Show
9. How the Claim Compares With the Research
10. What Is Not Known
11. Connections
12. Key Research Papers
13. Featured Videos

What the Presentation Said

Near the end of the webinar, the speaker answered a question from a listener whose father had cancer of the oesophagus (the food pipe) that had come back and spread. In reply, the speaker described an emotional and spiritual connection to cancer as one of the central parts of the approach taught at the clinic, and asked whether patients keep up their emotional and spiritual work once they return home after treatment.

The speaker then made the point this page examines, and repeated it for emphasis: that unresolved emotional trauma is often the hidden toxin that quietly drives disease at the cell level.

To illustrate it, the speaker described two patients, patient A and patient B, with a similar diagnosis. One does well and the other does not. The speaker's reasoning was that something must still be missing for the patient who does poorly, and suggested that most of the time the missing piece is emotional trauma that has not been resolved.

The speaker did not cite a study for this point. Earlier in the webinar the speaker had also linked parasites to depression and anxiety; that separate claim is covered on the sibling page Parasites, Mood and the Nervous System. The speaker's own forthcoming book on the subject is not discussed here.

The claim contains three separate ideas that research can test:

• that emotional stress or trauma helps cause cancer to begin;
• that it drives cancer that already exists, through effects on cells;
• that unresolved trauma is the usual reason one patient does worse than another with the same diagnosis.

Does Stress Raise the Risk of Getting Cancer?

This is the question with the most data. Researchers follow large groups of healthy people for years, measure their stress at the start, and count who later develops cancer. Studies like these are called prospective cohort studies. A meta-analysis pools the results of many such studies.

The most recent pooled review: no consistent link

A 2026 systematic review and meta-analysis gathered 19 prospective studies of stressful life events or perceived stress (how stressed people say they feel) and the later risk of overall, breast, prostate, colorectal and endometrial cancer. Neither stressful life events nor perceived stress was consistently associated with cancer risk. Some studies even found that high perceived stress went with lower risk. The authors rated the certainty of the evidence as very low: most studies used stress questionnaires that had not been validated, and most measured stress only once (Galicia Pacheco and colleagues, 2026).

Work stress in 116,000 Europeans

A pooled analysis of the original data from 12 European cohorts followed 116,056 working men and women for a median of 12 years, during which 5,765 cancers were diagnosed. High job strain (a demanding job with little control) was not associated with overall cancer risk (hazard ratio 0.97, 95% confidence interval 0.90 to 1.04), nor with colorectal, lung, breast or prostate cancer. A hazard ratio of 1 means no difference in risk. The authors concluded that work stress measured this way is unlikely to be an important risk factor for these cancers (Heikkilä and colleagues, 2013).

Stress and breast cancer in Copenhagen

The Copenhagen City Heart Study asked 6,689 women about their stress level in 1981 to 1983 and followed them for 18 years. Women reporting high stress had a lower, not higher, rate of breast cancer (hazard ratio 0.60). The researchers suggested that chronic stress may lower oestrogen production, and added that this did not make stress healthy (Nielsen and colleagues, 2005).

The loss of a child

One of the most severe stresses a person can live through is the death of a child. A Danish national register study compared 21,062 bereaved parents with 293,745 other parents for up to 18 years. Bereaved mothers had a slightly higher overall cancer risk 7 to 18 years later (relative risk 1.18), driven mainly by smoking-related cancers; there was no rise in breast cancer or in hormone-related or immune-related cancers. The authors suggested that the increase may reflect changes in lifestyle after bereavement, such as smoking (Li and colleagues, 2002).

Studies that did find a link

• A 2008 meta-analysis of 165 studies reported that stress-related psychosocial factors were associated with higher cancer incidence overall. In its subgroup analyses, stressful life experiences were not linked to higher incidence; coping styles and negative emotional responses were. The authors found evidence of publication bias (studies with positive findings being more likely to be published) and advised caution (Chida and colleagues, 2008).
• A 2026 United Kingdom Biobank cohort of 245,683 adults measured "allostatic load", a score built from 11 blood and body measurements meant to capture the body's wear and tear from chronic stress. Over a median of 13.5 years, a high score went with a 6% higher cancer risk (hazard ratio 1.06). The score includes measures such as blood sugar, blood pressure and body fat, which are themselves linked to cancer (Wang and colleagues, 2026).

Taken together, the largest and best-designed studies find either no link between psychological stress and the chance of getting cancer, or a small one that is hard to separate from smoking, drinking, weight and other habits.

Adverse Childhood Experiences and Cancer

The research on childhood trauma comes closest to the presentation's word "trauma". Adverse childhood experiences are events before the age of 18 such as abuse, neglect, violence in the home, or living with a parent who misused alcohol or drugs, was mentally ill, or was imprisoned.

The original Adverse Childhood Experiences Study

In 1998, a survey of 9,508 adults at a large health plan in California found that the more categories of childhood adversity a person reported, the more likely they were to smoke, drink heavily, use drugs, be severely obese and be physically inactive as adults. The number of categories also showed a graded relationship with adult diseases including heart disease, lung disease, liver disease and cancer (Felitti and colleagues, 1998).

Pooled studies since then

• A 2017 meta-analysis of 37 studies and 253,719 people found that adults who reported four or more adverse childhood experiences had roughly two to three times the odds of cancer compared with adults who reported none, and much higher odds of smoking, heavy drinking, drug use and mental ill health (Hughes and colleagues, 2017).
• A 2021 meta-analysis of 18 studies and 406,210 people found raised odds of cancer with two or three adverse experiences (odds ratio 1.35) and with four or more (odds ratio 2.17), compared with none (Hu and colleagues, 2021).

The likely pathway runs through known cancer causes

Most of these studies were cross-sectional or case-control (people were asked about their childhood after the fact), so they show association, not cause. A scoping review by researchers at the United States Centers for Disease Control and Prevention collected 155 studies and found that adverse childhood experiences were most consistently tied to established cancer risk factors, above all alcohol, obesity and tobacco. Far fewer studies looked at inflammation or infections, and none at hormones or immune suppression (Ports and colleagues, 2019).

In plain terms: childhood trauma is linked to higher cancer rates in adulthood, and much of that link appears to travel through smoking, drinking and weight, which are well-proven causes of cancer. Whether trauma acts on cells directly, apart from those habits, has not been shown in people.

Stress Hormones and Tumor Growth

The part of the claim about the "cell level" has real laboratory support, though mostly from animals. When the body is under stress, the sympathetic nervous system (the "fight or flight" system) releases adrenaline and noradrenaline. These hormones act on beta-adrenergic receptors, docking sites found on many cells, including some tumor cells and immune cells. Beta-blockers, such as Propranolol, are heart and blood-pressure medicines that block these receptors.

In mice

• In a mouse model of breast cancer, confining the animals (a standard way to stress mice) had little effect on the size of the original tumor but produced a 30-fold increase in spread to the lymph nodes and lungs. The effect ran through beta-adrenergic signalling and immune cells called macrophages, and treating the stressed mice with Propranolol blocked it (Sloan and colleagues, 2010).
• In mice with stomach cancer, chronic restraint stress raised stress hormones and sped tumor growth and spread; beta-blockers reversed this. In the same study, tissue from 100 human stomach cancers showed that more of the beta-2 receptor went with larger, more advanced tumors, which is a correlation, not proof of cause (Zhang and colleagues, 2019).
• A 2023 study in mice found that stress hormones acting through the beta-1 receptor push killer T cells, the immune cells that destroy cancer cells, into an exhausted, less active state. Blocking the receptor improved the response to immune checkpoint drugs in mouse melanoma and pancreatic cancer (Globig and colleagues, 2023).

A 2021 review summarised human and animal work showing that sympathetic nerves grow into tumors and can promote prostate cancer, breast cancer and melanoma, while the parasympathetic (calming) nerves promote some cancers and hold back others (Kamiya and colleagues, 2021).

In people

Human evidence is still early. In a randomised, placebo-controlled trial of 34 people having surgery for colorectal cancer, a combination of Propranolol and Etodolac (an anti-inflammatory drug) taken for 20 days around the operation improved molecular markers in the removed tumors that are linked to spread. Three-year recurrence was 12.5% with the drugs and 33.3% with placebo, a difference that was not statistically significant in a trial this small. The authors described it as a biomarker trial and called for larger trials (Haldar and colleagues, 2020).

These studies show that stress hormones can change how tumors and immune cells behave. They test stress as an activated hormone system, not emotional trauma as such, and the dramatic effects seen in mice have not been shown to translate into longer survival in people.

Depression, Anxiety and Survival

Depression and anxiety are common after a cancer diagnosis. A 2024 meta-analysis of 34 studies of 13,828 women with breast cancer put the share with significant psychological distress at about half (50%). Distress was more common in younger women, soon after diagnosis, during chemotherapy and when the cancer had spread (Tang and colleagues, 2024). This matters for the research below: being very ill can cause depression, not only the other way round.

What the meta-analyses report

• A 2009 meta-analysis found that, across 25 studies, death rates were up to 25% higher in people with cancer who had depressive symptoms, and up to 39% higher in those diagnosed with major or minor depression. Depression did not significantly predict cancer progression, based on only three studies. The authors called the added risk statistically significant but relatively small (Satin and colleagues, 2009).
• A 2020 meta-analysis of 51 cohort studies and over 2.6 million people found that depression and anxiety were linked to a 13% higher cancer incidence, 21% higher cancer death rate and 24% higher death rate from any cause among people with cancer. In absolute terms, that was about 34 extra cancer cases per 100,000 people per year. Symptoms of distress, as opposed to a clinical diagnosis, were not linked to higher incidence. The authors noted possible reverse causation and large differences between studies (Wang and colleagues, 2020, Molecular Psychiatry 25:1487).
• A 2020 meta-analysis of 17 studies and 282,203 women with breast cancer found that depression went with a higher risk of recurrence (hazard ratio 1.24) and of death from breast cancer (1.29); anxiety went with recurrence but not with death from breast cancer (Wang and colleagues, 2020, Molecular Psychiatry 25:3186).

Why the link is hard to read

Depression can affect survival through ordinary routes: missed appointments, stopping treatment early, poor sleep and appetite, less physical activity, smoking and drinking. It can also be a sign of more advanced illness, pain or the side effects of treatment. The studies above adjusted for some of these factors but could not remove them all, which is why their authors described the findings with caution.

Depression in people with cancer is treatable and is worth treating in its own right; the site's Depression page covers it in more detail.

Can Psychological Support Extend Survival?

If unresolved emotional distress drives cancer, then helping people work through it ought to help them live longer. This has been tested directly in randomised controlled trials, the strongest kind of study, where patients are assigned by chance to receive psychological support or not. The results are mixed, and the history of this question is instructive.

The trial that started it

In 1989, a trial of 86 women with metastatic breast cancer reported that those randomised to a year of weekly supportive group therapy, with self-hypnosis for pain, lived on average 36.6 months, compared with 18.9 months in the control group (Spiegel and colleagues, 1989). The finding drew wide attention and prompted several larger trials.

The trials that did not confirm it

• A Canadian multicentre trial of 235 women with metastatic breast cancer found that weekly supportive-expressive group therapy improved mood and reduced pain, especially in the most distressed women, but did not prolong survival (median 17.9 months with therapy versus 17.6 months without) (Goodwin and colleagues, 2001).
• An Australian trial of 227 women with advanced breast cancer found the same: the group therapy did not prolong survival, but it prevented and treated depression, reduced hopelessness and trauma symptoms, and improved social functioning. The factors that did predict survival were medical: treatment with chemotherapy and hormone therapy, spread to internal organs, and how advanced the cancer was at first diagnosis (Kissane and colleagues, 2007).
• The original research group repeated its own study with 125 women and reported that the earlier survival finding was not replicated (median 30.7 months with therapy versus 33.3 months in controls). An exploratory analysis found longer survival with therapy in a small subgroup of 25 women whose tumors lacked oestrogen receptors; the authors said more research was needed to know whether this was real (Spiegel and colleagues, 2007).

A positive trial in earlier-stage cancer

In a trial of 227 women recently operated on for breast cancer that had spread only to nearby lymph nodes, a year of psychologist-led small-group sessions aimed at reducing stress, improving mood, changing health habits and keeping up with cancer treatment was followed, over a median of 11 years, by a lower risk of recurrence (hazard ratio 0.55) and of death from breast cancer (hazard ratio 0.44) compared with assessment alone (Andersen and colleagues, 2008). The intervention included support for sticking with treatment and healthier habits, so it is not possible to say which part made the difference.

The pooled picture

A 2016 meta-analysis of 13 randomised trials found a modest survival benefit at one and two years for people who received psychosocial interventions, but no difference at four years. Individually delivered interventions showed no survival benefit at any time point. The authors concluded that psychosocial interventions showed only short-term improvements in survival (Fu and colleagues, 2016).

What these trials do agree on is that psychological support reliably improves mood, distress, pain and quality of life for many people with cancer. That benefit stands on its own, whatever the effect on survival.

Why Two Similar Patients Can Fare Differently

The speaker's example of patient A and patient B describes something every cancer doctor sees. Research explains much of it without needing an emotional cause:

• The tumor itself differs. Two cancers with the same name and stage can carry different genetic changes, grow at different speeds and respond differently to the same drug. In the Australian group-therapy trial above, survival was predicted by medical factors, not by the therapy (Kissane and colleagues, 2007).
• Treatment differs. Whether a person can receive, tolerate and complete chemotherapy, hormone therapy or surgery changes outcomes.
• General health differs. Age, other illnesses, smoking, weight, fitness and nutrition all affect how well a person withstands cancer and its treatment.
• Chance plays a part. Even in identical-looking cases, some of the difference in outcome cannot be explained by anything measured.

Depression and distress may add a small amount to this picture, as the meta-analyses above suggest, partly through effects on treatment and habits. No study was found that measured "unresolved emotional trauma" in people with cancer and showed it to be the usual reason one patient does worse than another.

What the Research Does Not Show

Ideas that link cancer to emotions can leave people with cancer feeling that they caused their illness, or that a recurrence means they did not heal emotionally enough. The research reviewed on this page does not support that.

• Large prospective studies of perceived stress, stressful life events and work stress find no consistent rise in the chance of getting cancer (Galicia Pacheco and colleagues, 2026; Heikkilä and colleagues, 2013).
• Where stress or trauma is linked to cancer, a large part of the link runs through smoking, alcohol and weight (Ports and colleagues, 2019; Li and colleagues, 2002).
• Three of four survival trials of group psychological therapy for metastatic breast cancer found no survival benefit, even though the therapy helped people feel better (Goodwin and colleagues, 2001; Kissane and colleagues, 2007; Spiegel and colleagues, 2007).
• The added risk linked to depression is described by researchers as small, and partly explained by illness causing depression rather than the reverse (Satin and colleagues, 2009; Wang and colleagues, 2020).

Feeling frightened, sad or angry after a cancer diagnosis is common, and the evidence does not indicate that these feelings make the cancer grow. Emotional support has value for wellbeing and quality of life regardless of any effect on the tumor. Decisions about cancer treatment, and about care for depression, anxiety or past trauma, belong with a clinician.

How the Claim Compares With the Research

Supported in part

• Stress biology can act on tumors "at the cell level": in mice, stress hormones acting through beta-adrenergic receptors increase spread and weaken anti-tumor immune cells (Sloan and colleagues, 2010; Globig and colleagues, 2023). In people this rests so far on tissue correlations and one small biomarker trial (Haldar and colleagues, 2020).
• Childhood trauma is associated with higher cancer rates in adulthood (Hughes and colleagues, 2017; Hu and colleagues, 2021), with much of the link running through smoking, alcohol and obesity (Ports and colleagues, 2019).
• Depression and anxiety are associated with somewhat shorter survival in people with cancer, by amounts the authors describe as small, with possible reverse causation (Satin and colleagues, 2009; Wang and colleagues, 2020).

Not supported

• That emotional stress is a hidden driver of cancer onset: the largest prospective studies and the most recent meta-analysis find no consistent association between psychological stress and cancer incidence (Galicia Pacheco and colleagues, 2026; Heikkilä and colleagues, 2013).
• That resolving emotional distress reliably changes the course of the cancer: most randomised survival trials of psychological therapy were null, and pooled analysis found at most a short-term survival benefit (Fu and colleagues, 2016).

No research found

• No study was found that measured unresolved emotional trauma specifically in people with cancer and showed it explains why one patient does better than another with the same diagnosis.
• No trial was found testing the clinic's own emotional and spiritual programme against usual care.

What Is Not Known

• Whether the stress-hormone effects seen in mice happen to a meaningful degree in people, and in which cancers.
• Whether blocking beta-adrenergic receptors around surgery or alongside immunotherapy improves survival; so far the human trials are small and measure biomarkers.
• How much of the link between depression and survival is cause and how much is effect, since advanced illness and treatment side effects can themselves cause depression.
• Whether childhood trauma affects cancer risk through any route other than the habits and conditions it is known to be linked to.
• Why the 1989 group-therapy result was not repeated, and whether some subgroups, such as women with oestrogen-receptor-negative breast cancer, respond differently.
• How best to measure stress and trauma: most studies used a single questionnaire at one point in time, which the 2026 meta-analysis identified as a major weakness.

Connections

• Cancer and Parasites
• Parasites, Mood and the Nervous System
• Nutrition in Cancer Care and Medical Training
• Detox During Chemotherapy: What the Research Shows
• How Parasites Can Drive Cancer: The Mechanisms
• Cancer
• Breast Cancer
• Depression
• Post-Traumatic Stress Disorder
• Anxiety
• Stress Management
• Meditation
• The Stress and Cortisol Axis
• Cortisol Test

Key Research Papers

1. Galicia Pacheco SI, Petrova D, Garrido D, et al. The relationship between psychological stress and cancer incidence: a systematic review and meta-analysis. Health Psychol Rev. 2026;20(2):330-356. PubMed PMID: 41332309
2. Heikkilä K, Nyberg ST, Theorell T, et al. Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women. BMJ. 2013;346:f165. PubMed PMID: 23393080
3. Nielsen NR, Zhang ZF, Kristensen TS, et al. Self reported stress and risk of breast cancer: prospective cohort study. BMJ. 2005;331(7516):548. PubMed PMID: 16103031
4. Li J, Johansen C, Hansen D, et al. Cancer incidence in parents who lost a child: a nationwide study in Denmark. Cancer. 2002;95(10):2237-42. PubMed PMID: 12412179
5. Chida Y, Hamer M, Wardle J, et al. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5(8):466-75. PubMed PMID: 18493231
6. Wang P, Peng Y, Du H, et al. Allostatic load, personality traits, and cancer risk: A prospective cohort study. Psychol Med. 2026;56:e7. PubMed PMID: 41486949
7. Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med. 1998;14(4):245-58. PubMed PMID: 9635069
8. Hughes K, Bellis MA, Hardcastle KA, et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. Lancet Public Health. 2017;2(8):e356-e366. PubMed PMID: 29253477
9. Hu Z, Kaminga AC, Yang J, et al. Adverse childhood experiences and risk of cancer during adulthood: A systematic review and meta-analysis. Child Abuse Negl. 2021;117:105088. PubMed PMID: 33971569
10. Ports KA, Holman DM, Guinn AS, et al. Adverse Childhood Experiences and the Presence of Cancer Risk Factors in Adulthood: A Scoping Review of the Literature From 2005 to 2015. J Pediatr Nurs. 2019;44:81-96. PubMed PMID: 30683285
11. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70(18):7042-52. PubMed PMID: 20823155
12. Zhang X, Zhang Y, He Z, et al. Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2. Cell Death Dis. 2019;10(11):788. PubMed PMID: 31624248
13. Globig AM, Zhao S, Roginsky J, et al. The β(1)-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature. 2023;622(7982):383-392. PubMed PMID: 37731001
14. Kamiya A, Hiyama T, Fujimura A, et al. Sympathetic and parasympathetic innervation in cancer: therapeutic implications. Clin Auton Res. 2021;31(2):165-178. PubMed PMID: 32926324
15. Haldar R, Ricon-Becker I, Radin A, et al. Perioperative COX2 and β-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial. Cancer. 2020;126(17):3991-4001. PubMed PMID: 32533792
16. Tang WZ, Mangantig E, Iskandar YHP, et al. Prevalence and associated factors of psychological distress among patients with breast cancer: a systematic review and meta-analysis. BMJ Open. 2024;14(9):e077067. PubMed PMID: 39327054
17. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer. 2009;115(22):5349-61. PubMed PMID: 19753617
18. Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487-1499. PubMed PMID: 31745237
19. Wang X, Wang N, Zhong L, et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Mol Psychiatry. 2020;25(12):3186-3197. PubMed PMID: 32820237
20. Spiegel D, Bloom JR, Kraemer HC, et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2(8668):888-91. PubMed PMID: 2571815
21. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345(24):1719-26. PubMed PMID: 11742045
22. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology. 2007;16(4):277-86. PubMed PMID: 17385190
23. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer. 2007;110(5):1130-8. PubMed PMID: 17647221
24. Andersen BL, Yang HC, Farrar WB, et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer. 2008;113(12):3450-8. PubMed PMID: 19016270
25. Fu WW, Popovic M, Agarwal A, et al. The impact of psychosocial intervention on survival in cancer: a meta-analysis. Ann Palliat Med. 2016;5(2):93-106. PubMed PMID: 27121737

PubMed Topic Searches

1. Psychological stress and cancer incidence (prospective studies)
2. Adverse childhood experiences and cancer risk
3. Beta-adrenergic signalling, stress and tumor progression
4. Depression and cancer mortality (meta-analyses)
5. Psychosocial interventions and cancer survival (randomised trials)

Featured Videos